Vertex (VRTX) reported interim data on a Phase II study targeting Cystic Fibrosis, which affects 30,000 in the United States and 70,000 worldwide. Previously, the company's KALYDECO drug - which won FDA approval in January - could only be used to treat about 4% of those patients.
Robert Weinstein submits:
The Way means inducing the people to have the same aim as the leadership, so that they will share death and share life, without fear of danger. -- Sun Tsu, The Art of War.
Vertex Pharmaceuticals Incorporated (VRTX) of Cambridge, MA was up strongly today to close at $49.95 a share.
Vertex Pharmaceuticals Inc released corrected data involving its cystic fibrosis treatments on Tuesday that lowered the number of patients who showed certain levels of improved lung function, sending its ...